Enigma of COVID-19: is “multisystem inflammatory syndrome in adults” (MIS-A) predictable?

被引:0
作者
Istemi Serin
Nagehan Didem Sari
Murat Gunaltili
Ayse Karakilic
Begum Gulesir
Beyza Kal Kolik
Gulnihal Cevik
Hilal Sungurlu
Melike Keskin
Muhammed Baltik
Onurhan Cakmak
Tahir Alper Cinli
机构
[1] Istanbul Training and Research Hospital,Department of Hematology
[2] University of Health Sciences,Department of Clinical Microbiology and Infectious Diseases
[3] Istanbul Training and Research Hospital,Department of Internal Medicine
[4] University of Health Sciences,undefined
[5] Istanbul Training and Research Hospital,undefined
[6] University of Health Sciences,undefined
来源
BMC Infectious Diseases | / 22卷
关键词
COVID-19; Multisystem inflammatory syndrome in adults (MIS-a); Mortality; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 133 条
[1]  
Dhama K(2020)Coronavirus disease 2019-COVID-19 Clin Microbiol Rev 33 e00028-e120
[2]  
Khan S(2020)Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2 J Infect 80 394-400
[3]  
Tiwari R(2020)Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis Lancet Infect Dis 20 1043-1050
[4]  
Sircar S(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 395 1054-1062
[5]  
Bhat S(2020)Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet 395 507-513
[6]  
Malik YS(2020)The trinity of COVID-19: immunity, inflammation and intervention Nat Rev Immunol 20 363-374
[7]  
Xu YH(2020)COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 395 1033-1034
[8]  
Dong JH(2020)The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease Autoimmun Rev 19 e437-e445
[9]  
An WM(2020)Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Lancet Rheumatol 2 10970-10975
[10]  
Lv XY(2020)Effective treatment of severe COVID-19 patients with tocilizumab Proc Natl Acad Sci U S A. 117 1450-1456